Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | HMGCR | P04035 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CPT2 | P23786 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ACLY | P53396 | 3/20 | 0.32 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26973337 | 0.78 | TSHR (0.35) | CYP2C19HIF1ATSHRCYP2D6ALDH1A1 | |
| SCHEMBL10597899 | 0.76 | ALDH1A1 (0.44) | CYP2C19HIF1ATSHRCYP2D6HMGCR | |
| SCHEMBL9485466 | 0.76 | CYP2C19 (0.48) | CYP2C19HIF1ATSHRCYP2D6HMGCR | |
| SCHEMBL5975709 | 0.75 | CYP2C19 (0.46) | CYP2C19HIF1ATSHRCYP2D6HMGCR | |
| SCHEMBL21569414 | 0.74 | HMGCR (0.48) | CYP2C19HIF1ATSHRCYP2D6HMGCR | |
| SCHEMBL11882298 | 0.73 | CYP2C19 (0.44) | CYP2C19HIF1ATSHRCYP2D6HMGCR | |
| SCHEMBL27447577 | 0.73 | CYP2C19 (0.44) | CYP2C19HIF1ATSHRCYP2D6HMGCR | |
| SCHEMBL5176549 | 0.73 | CYP2C19 (0.44) | CYP2C19HIF1ATSHRCYP2D6HMGCR | |
| SCHEMBL8939852 | 0.71 | CYP2D6 (0.42) | CYP2C19HIF1ATSHRCYP2D6HMGCR | |
| SCHEMBL20347147 | 0.71 | CYP4F2 (0.39) | CPT2FFAR1TDP1ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180186827-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186827-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | NT5E, ENTPD5, NT5C2 | CYP2C19 977/4885HIF1A 1486/4885TSHR 2756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.